Clinical Trial Results: Early GLP-1 Receptor Agonist and SGLT2 Inhibitor Add-On Strategies in Adults With Obesity, Type 2 Diabetes, Cardiovascular-Kidney-Metabolic Syndrome Stage 2-3, and Metabolic Dysfunction-Associated Steatotic Liver Disease

View source ↗

Summary

Clinical trial results for early GLP-1 receptor agonist and SGLT2 inhibitor add-on strategies in adults with obesity, type 2 diabetes, cardiovascular-kidney-met…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular-kidney-metabolic Syndrome
• Metabolic Dysfunction-associated Steatotic Liver Disease
• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• GLP-1 receptor agonist (early-stage)
• SGLT2 inhibitor (early-stage)

Snippet

Sponsor: Chung Shan Medical University | Conditions: Obesity Type 2 Diabetes Mellitus, Cardiovascular-kidney-metabolic Syndrome | Status: COMPLETED | Results posted: 2026-06-25